GOSSAMER BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.668 USD | -0.30% |
|
-14.77% | -26.79% |
| Mar. 13 | Transcript : Gossamer Bio, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 07:30 AM | |
| Mar. 12 | Gossamer Bio Announces Board of Directors Appointments | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 953.2 | 701 | 854.3 | 204.5 | 205.7 | 151.1 | - | - |
| Enterprise Value (EV) 1 | 579.8 | 360.8 | 708.2 | 168.2 | 118.3 | 137.8 | 127.3 | 123.6 |
| P/E ratio | -4.75 x | -2.72 x | -3.61 x | -0.8 x | -0.77 x | -0.9 x | -0.95 x | -1.43 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | 3.57 x |
| EV / Revenue | - | - | - | - | - | - | - | 2.92 x |
| EV / EBITDA | -3.13 x | -1.55 x | -3.3 x | -0.78 x | -0.65 x | -0.81 x | -0.71 x | -0.8 x |
| EV / FCF | -3.92 x | -2.03 x | -3.72 x | -0.9 x | -0.74 x | -1.09 x | -0.99 x | -1.49 x |
| FCF Yield | -25.5% | -49.3% | -26.9% | -111% | -135% | -91.7% | -101% | -66.9% |
| Price to Book | 2.43 x | - | - | 17 x | 3.28 x | -1.73 x | -1.55 x | -7.94 x |
| Nbr of stocks (in thousands) | 60,985 | 72,496 | 75,538 | 94,256 | 225,409 | 226,219 | - | - |
| Reference price 2 | 15.63 | 9.670 | 11.31 | 2.170 | 0.9125 | 0.6680 | 0.6680 | 0.6680 |
| Announcement Date | 3/24/20 | 2/25/21 | 3/3/22 | 3/17/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 42.28 |
| EBITDA 1 | -185.2 | -232.6 | -214.4 | -216.8 | -182.2 | -170.7 | -180.2 | -155.3 |
| EBIT 1 | -186.1 | -234 | -216.1 | -218.6 | -183.8 | -172 | -186.4 | -144 |
| Operating Margin | - | - | - | - | - | - | - | -340.47% |
| Earnings before Tax (EBT) 1 | -180.3 | -243.4 | -234 | -229.4 | -179.8 | -173.5 | -190.4 | -138.3 |
| Net income 1 | -180.3 | -243.4 | -234 | -229.4 | -179.8 | -179.9 | -196.4 | -150.4 |
| Net margin | - | - | - | - | - | - | - | -355.79% |
| EPS 2 | -3.290 | -3.550 | -3.130 | -2.710 | -1.180 | -0.7398 | -0.7053 | -0.4676 |
| Free Cash Flow 1 | -147.8 | -177.9 | -190.4 | -187.4 | -159.2 | -126.4 | -128 | -82.7 |
| FCF margin | - | - | - | - | - | - | - | -195.59% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/24/20 | 2/25/21 | 3/3/22 | 3/17/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | -55.21 | -51.21 | -53.89 | -53.41 | -55.56 | -53.9 | -47.48 | -45.8 | -40.1 | -48.74 | -35.2 | -36.3 | -36.4 | -37.5 | - |
| EBIT 1 | -55.66 | -51.66 | -54.34 | -53.87 | -56.02 | -54.36 | -47.94 | -46.3 | -40.49 | -49.03 | -41.29 | -42.33 | -43.32 | -44.88 | -46.51 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -60.25 | -56.28 | -57.78 | -56.47 | -59.36 | -55.76 | -49.16 | -42.5 | -40.01 | -48.15 | -41.35 | -42.69 | -43.84 | -45.61 | -50.08 |
| Net income 1 | -60.25 | -56.28 | -57.78 | -56.47 | -59.36 | -55.76 | -49.16 | -42.5 | -40.01 | -48.15 | -43.11 | -44.34 | -45.43 | -47.06 | -50.08 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.8000 | -0.7400 | -0.7600 | -0.7400 | -0.6500 | -0.5900 | -0.5200 | -0.4500 | -0.2100 | -0.2100 | -0.1878 | -0.1880 | -0.1911 | -0.1913 | -0.2052 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 3/3/22 | 5/10/22 | 8/9/22 | 11/3/22 | 3/17/23 | 5/9/23 | 8/8/23 | 11/9/23 | 3/5/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 373 | 340 | 146 | 36.4 | 87.4 | 13.3 | 23.8 | 27.5 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -148 | -178 | -190 | -187 | -159 | -126 | -128 | -82.7 |
| ROE (net income / shareholders' equity) | -155% | -72.3% | -106% | -344% | -480% | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | -74.5% | - | - | - | - |
| Assets 1 | - | - | - | 308.1 | - | - | - | - |
| Book Value Per Share 2 | 6.440 | - | - | 0.1300 | 0.2800 | -0.3900 | -0.4300 | -0.0800 |
| Cash Flow per Share | -2.650 | -2.570 | -2.520 | -2.210 | - | - | - | - |
| Capex 1 | 2.97 | 1.5 | 1.55 | 0.41 | - | 0.83 | 1.89 | 2.12 |
| Capex / Sales | - | - | - | - | - | - | - | 5.01% |
| Announcement Date | 3/24/20 | 2/25/21 | 3/3/22 | 3/17/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
0.668
USD
Average target price
5.719
USD
Spread / Average Target
+756.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.79% | 151M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- GOSS Stock
- Financials Gossamer Bio, Inc.
